Treating tobacco dependence in a medical setting

CA Cancer Journal for Clinicians

Volumn 59, Issue 5, 2009, Pages 314-326

  Hurt, Richard D ^a   Ebbert, Jon O ^a   Hays, J Taylor ^a   McFadden, David D ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; NICOTINE; NICOTINE GUM; VARENICLINE;

AGITATION; BEHAVIOR DISORDER; BEHAVIOR THERAPY; CLINICAL DECISION MAKING; DEPRESSION; DRUG EFFICACY; EVIDENCE BASED PRACTICE; FOOD AND DRUG ADMINISTRATION; HEALTH CARE; HEALTH CARE DELIVERY; HEALTH CARE PERSONNEL; HEALTH CARE POLICY; HOSTILITY; HUMAN; LOZENGE; MEDICAL ASSESSMENT; MENTAL DISEASE; MOOD DISORDER; NAUSEA; NICOTINE REPLACEMENT THERAPY; PATIENT CARE; PATIENT COUNSELING; PHYSICIAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; PUBLIC HEALTH SERVICE; REVIEW; SIDE EFFECT; SMOKELESS TOBACCO; SMOKING CESSATION; SUICIDAL IDEATION; SUICIDE ATTEMPT; SUSTAINED DRUG RELEASE; TOBACCO DEPENDENCE; TREATMENT OUTCOME; VIVID DREAM;

ANIMALS; BENZAZEPINES; BUPROPION; COTININE; DOPAMINE UPTAKE INHIBITORS; HUMANS; NICOTINE; PRACTICE GUIDELINES AS TOPIC; QUINOXALINES; RECEPTORS, NICOTINIC; SMOKING CESSATION; TOBACCO USE CESSATION; TOBACCO USE DISORDER; TREATMENT OUTCOME; UNITED STATES; UNITED STATES PUBLIC HEALTH SERVICE;

EID: 70349216838     PISSN: 00079235     EISSN: 15424863     Source Type: Journal    
DOI: 10.3322/caac.20031     Document Type: Review

References (84)

1. Fiore M, Baker T, Jaen C, et al. Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline. Rockville, Md: US Department of Health & Human Services, Public Health Service; 2008.
2. Swartz SH, Cowan TM, Klayman JE, et al. Use and effectiveness of tobacco telephone counseling and nicotine therapy in Maine. Am J Prev Med. 2005;29:288-294.
3. Brody AL, Mandelkern MA, London ED, et al. Cigarette smoking saturates brain alpha 4 beta 2 nicotinic acetylcholine receptors. Arch Gen Psychiatry. 2006;63:907-915.
4. Watkins SS, Koob GF, Markou A. Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal. Nicotine Tob Res. 2000;2:19-37.
5. Balfour DJK. The neurochemical mechanisms underlying nicotine tolerance and dependence. In Pratt JA, ed. The Biological Basis of Drug Tolerance and Dependence. London, UK: Academic Press; 1991:121-151.
6. Perry DC, Davila-Garcia MI, Stockmeier CA, et al. Increased nicotinic receptors in brains from smokers: membrane binding and autoradiography studies. J Pharmacol Exp Ther. 1999;289:1545-1552.
7. Hope BT, Nagarkar D, Leonard S, et al. Long-term upregulation of protein kinase A and adenylate cyclase levels in human smokers. J Neurosci. 2007;27:1964-1972. (Pubitemid 46310298)
8. Kenny PJ, Markou A. Conditioned nicotine withdrawal profoundly decreases the activity of brain reward systems. J Neurosci. 2005;25:6208-6212. (Pubitemid 40923487)
9. Dale LC, Hurt RD, Offord KP, et al. High-dose nicotine patch therapy. Percentage of replacement and smoking cessation. JAMA. 1995;274:1353-1358.
10. Gourlay SG, Benowitz NL. Arteriovenous differences in plasma concentration of nicotine and catecholamines and related cardiovascular effects after smoking, nicotine nasal spray, and intravenous nicotine. Clin Pharmacol Ther. 1997;62:453-463.
11. Ho M, Mwenifumbo J, Al Koudsi N, et al. Association of nicotine metabolite ratio and CYP2A6 genotype with smoking cessation treatment in African-American light smokers. Clin Pharmacol Ther. 2009;85:635-643.
12. Henningfield JE, Stapleton JM, Benowitz NL, et al. Higher levels of nicotine in arterial than in venous blood after cigarette smoking. Drug Alcohol Depend. 1993;33:23-29. (Pubitemid 23219906)
13. Jacob Pr, Yu L, Shulgin AT, et al. Minor tobacco alkaloids as biomarkers for tobacco use: comparison of users of cigarettes, smokeless tobacco, cigars, and pipes. Am J Public Health. 1999;89:731-736. (Pubitemid 29282738)
14. Moyer TP, Charlson JR, Enger RJ, et al. Simultaneous analysis of nicotine, nicotine metabolites, and tobacco alkaloids in serum or urine by tandem mass spectrometry, with clinically relevant metabolic profiles. Clin Chem. 2002;48:1460-1471.
15. Jacob P 3rd, Hatsukami D, Severson H, et al. Anabasine and anatabine as biomarkers for tobacco use during nicotine replacement therapy. Cancer Epidemiol Biomarkers Prev. 2002;11:1668-1673.
16. Henningfield JE, Fant RV, Buchhalter AR, et al. Pharmacotherapy for nicotine dependence. CA Cancer J Clin. 2005;55:281-299; quiz 322-325.
17. Ebbert JO. Combination treatment with varenicline and nicotine replacement therapy. Nicotine Tob Res. 2009;11:572-576.
18. Shiffman S, Dresler CM, Hajek P, et al. Efficacy of a nicotine lozenge for smoking cessation. Arch Intern Med. 2002;162:1267-1276. (Pubitemid 34595033)
19. Schneider NG, Olmstead R, Mody FV, et al. Efficacy of a nicotine nasal spray in smoking cessation: a placebo-controlled, double-blind trial. Addiction. 1995;90:1671-1682. (Pubitemid 26315887)
20. Hurt RD, Offord KP, Croghan IT, et al. Temporal effects of nicotine nasal spray and gum on nicotine withdrawal symptoms. Psychopharmacology (Berl). 1998;140:98-104. (Pubitemid 28524313)
21. Schneider NG, Lunell E, Olmstead RE, et al. Clinical pharmacokinetics of nasal nicotine delivery. A review and comparison to other nicotine systems. Clin Pharmacokinet. 1996;31:65-80. (Pubitemid 26238204)
22. Leischow SJ, Nilsson F, Franzon M, et al. Efficacy of the nicotine inhaler as an adjunct to smoking cessation. Am J Health Behav. 1996;20:364-371. (Pubitemid 126439307)
23. Bergstrom M, Nordberg A, Lunell E, et al. Regional deposition of inhaled 11C-nicotine vapor in the human airway as visualized by positron emission tomography. Clin Pharm Ther. 1995;57:309-317.
24. Hurt RD, Dale LC, Offord KP, et al. Serum nicotine and cotinine levels during nicotine-patch therapy. Clin Pharm Ther. 1993;54:98-106. (Pubitemid 23227525)
25. Hurt RD, Dale LC, Fredrickson PA, et al. Nicotine patch therapy for smoking cessation combined with physician advice and nurse follow-up. One-year outcome and percentage of nicotine replacement. JAMA. 1994;271:595-600.
26. Hughes JR. Treatment of nicotine dependence. Is more better? JAMA. 1995;274:1390-1391.
27. Fredrickson PA, Hurt RD, Lee GM, et al. High dose transdermal nicotine therapy for heavy smokers: safety, tolerability and measurement of nicotine and cotinine levels. Psychopharmacology (Berl). 1995;122:215-222.
28. Hughes JR, Lesmes GR, Hatsukami DK, et al. Are higher doses of nicotine replacement more effective for smoking cessation? Nicotine Tob Res. 1999;1:169-174.
29. Jorenby DE, Smith SS, Fiore MC, et al. Varying nicotine patch dose and type of smoking cessation counseling. JAMA. 1995;274:1347-1352.
30. Tonnesen P, Paoletti P, Gustavsson G, et al. Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE trial. Collaborative European Anti-Smoking Evaluation. European Respiratory Society. Eur Respir J. 1999;13:238-246.
31. Kenford SL, Fiore MC, Jorenby DE, et al. Predicting smoking cessation. Who will quit with and without the nicotine patch. JAMA. 1994;271:589-594.
32. Steinberg MB, Greenhaus S, Schmelzer AC, et al. Triple-combination pharmacotherapy for medically ill smokers: a randomized trial. Ann Intern Med. 2009;150:447-454.
33. Ascher JA, Cole JO, Colin JN, et al. Bupropion: a review of its mechanism of antidepressant activity. J Clin Psychiatry. 1995;56:395-401.
34. Clarke PB. Nicotine dependence - mechanisms and therapeutic strategies. Biochem Soc Symp. 1993;59:83-95.
35. DiChiara G, Imperato A. Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci U S A. 1988;85:5274-5278. (Pubitemid 18192948)
36. Pontieri FE, Tanda G, Orzi F, et al. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996;382:255-257. (Pubitemid 26251360)
37. Fryer JD, Lukas RJ. Noncompetitive functional inhibition at diverse, human nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine and ibogaine. J Pharmacol Exp Ther. 1999;288:88-92.
38. Slemmer JE, Martin BR, Damaj MI. Bupropion is a nicotinic antagonist. J Pharmacol Exp Ther. 2000;295:321-327.
39. Hurt R, Sachs D, Glover E, et al. A comparison of sustained-release bupropion and placebo for smoking cessation. N Engl J Med. 1997;337:1195-1202. (Pubitemid 27454451)
40. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation: a randomized, controlled trial. Ann Intern Med. 2001;135:423-433.
41. Gonzales DH, Nides MA, Ferry LH, et al. Bupropion SR as an aid to smoking cessation in smokers treated previously with bupropion: a randomized placebo-controlled study. Clin Pharmacol Ther. 2001;69:438-444.
42. Tashkin D, Kanner R, Bailey W, et al. Smoking cessation in patients with chronic obstructive pulmonary disease: a double-blind, placebo-controlled, randomised trial. Lancet. 2001;357:1571-1575. (Pubitemid 32488814)
43. Tonstad S, Farsang C, Klaene G, et al. Bupropion SR for smoking cessation in smokers with cardiovascular disease: a multicentre, randomised study. Eur Heart J. 2003;24:946-955. (Pubitemid 36559988)
44. Jorenby DE, Leischow SJ, Nides M, et al. A controlled trial of sustained-release bupropion, a nicotine patch, or both for smoking cessation.NEngl J Med. 1999;340:685-691. (Pubitemid 29110752)
45. Rollema H, Chambers LK, Coe JW, et al. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid. Neuropharmacology. 2007;52:985-994. (Pubitemid 46227486)
46. Jorenby DE, Hays JT, Rigotti NA, et al. Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial. JAMA. 2006;296:56-63.
47. Gonzales D, Rennard SI, Nides M, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA. 2006;296:47-55.
48. Tonstad S, Tonnesen P, Hajek P, et al. Effect of maintenance therapy with varenicline on smoking cessation: a randomized controlled trial. JAMA. 2006;296:64-71.
49. McClure JB, Swan GE, Jack L, et al. Mood, side-effects and smoking outcomes among persons with and without probable lifetime depression taking varenicline. J Gen Intern Med. 2009;24:563-569.
50. Croghan IT, Hurt RD, Dakhil SR, et al. Randomized comparison of a nicotine inhaler and bupropion for smoking cessation and relapse prevention. Mayo Clin Proc. 2007;82:186-195. (Pubitemid 46198478)
51. Ebbert JO, Croghan IT, Sood A, et al. Varenicline and bupropion sustained-release combination therapy for smoking cessation. Nicotine Tob Res. 2009;11:234-239.
52. Hays JT, Ebbert JO. Bupropion sustained release for treatment of tobacco dependence. Mayo Clin Proc. 2003;78:1020-1024; quiz 1024.
53. National Toxicology Program. Report on Carcinogens. 11th ed. Washington, DC: US Department of Health and Human Services, Public Health Service, National Toxicology Program.
54. Ernster VL, Grady DG, Greene JC, et al. Smokeless tobacco use and health effects among baseball players. JAMA. 1990;264:218-224.
55. Fisher MA, Taylor GW, Tilashalski KR. Smokeless tobacco and severe active periodontal disease, NHANES III. J Dent Res. 2005;84:705-710. (Pubitemid 43827825)
56. Mattson ME, Winn DM. Smokeless tobacco: association with increased cancer risk. Natl Cancer Inst Monogr. 1989(8):13-16. (Pubitemid 19249703)
57. Stockwell HG, Lyman GH. Impact of smoking and smokeless tobacco on the risk of cancer of the head and neck. Head Neck Surg. 1986;9:104-110.
58. Goodman MT, Morgenstern H, Wynder EL. A case-control study of factors affecting the development of renal cell cancer. Am J Epidemiol. 1986;124:926-941. (Pubitemid 17207261)
59. Muscat JE, Hoffmann D, Wynder EL. The epidemiology of renal cell carcinoma. A second look. Cancer. 1995;75:2552-2557.
60. Muscat JE, Stellman SD, Hoffmann D, et al. Smoking and pancreatic cancer in men and women. Cancer Epidemiol Biomarkers Prev. 1997;6:15-19. (Pubitemid 27030422)
61. Henley SJ, Thun MJ, Connell C, et al. Two large prospective studies of mortality among men who use snuff or chewing tobacco (United States). Cancer Causes Control. 2005;16:347-358. (Pubitemid 40897827)
62. Substance Abuse and Mental Health Services Administration. Results from the 2006 National Survey on Drug Use and Health: National Findings. Available at: http://www.oas.samhsa.gov/NSDUH/2k6NSDUH/2k6results.cfm#4.4. Accessed November 6, 2007.
63. Substance Abuse and Mental Health Services Administration, Office of Applied Studies. Results from the 2007 National Survey on Drug Use and Health: National Findings. Rockville, Md: Department of Health and Human Services, Substance Abuse and Mental Health Services Administration, Office of Applied Studies; 2007. Available at: http://www.oas.samhsa.gov/NSDUH/2k7NSDUH/ 2k7Results.cfm#Ch4. Accessed November 6, 2007.
64. Foley S. BAT's US subsidiary puts its faith in chewing tobacco. The Independent. April 26, 2006. Available at: http://www.independent.co.uk/news/ business/news/bats-us-subsidiary-puts-its-faith-in-chewingtobacco-475621.html. Accessed November 4, 2007.
65. Campaign for Tobacco Free Kids. R.J. Reynolds Entry Into Smokeless Tobacco Market Cause For Major Concern. Available at: http://www. tobaccofreekids.org/Script/DisplayPressRelease.php3?Display=911. Accessed December 15, 2007.
66. McNeill A. Harm reduction. BMJ. 2004;328:885-887.
67. NIH State-of-the-Science Panel. National Institutes of Health State-of-the-Science conference statement: tobacco use: prevention, cessation, and control. Ann Intern Med. 2006;145:839-844. (Pubitemid 351650337)
68. Severson H. Enough Snuff: ST Cessation From the Behavioral, Clinical, and Public Health Perspectives. NIH Pub. No.93-3461. Bethesda, Md: National Institutes of Health; 1992.
69. Ebbert JO, Montori V, Vickers KS, et al. Interventions for smokeless tobacco use cessation. Cochrane Database Syst Rev. 2007(4):CD004306. (Pubitemid 351805262)
70. Severson HH. What have we learned from 20 years of research on smokeless tobacco cessation? Am J Med Sci. 2003;326:206-211. (Pubitemid 37271394)
71. Dale LC, Ebbert JO, Glover ED, et al. Bupropion SR for the treatment of smokeless tobacco use. Drug Alcohol Depend. 2007;90:56-63. (Pubitemid 46935371)
72. Ebbert JO, Dale LC, Patten CA, et al. Effect of high-dose nicotine patch therapy on tobacco withdrawal symptoms among smokeless tobacco users. Nicotine Tob Res. 2007;9:43-52.
73. Ebbert JO, Dale LC, Severson H, et al. Nicotine lozenges for the treatment of smokeless tobacco use. Nicotine Tob Res. 2007;9:233-240. (Pubitemid 47009069)
74. Smith-Simone S, Maziak W, Ward KD, et al. Waterpipe tobacco smoking: knowledge, attitudes, beliefs, and behavior in two U.S. samples. Nicotine Tob Res. 2008;10:393-398. (Pubitemid 351201323)
75. National Cancer Institute, National Institutes of Health. Cigars: Health Effects and Trends. NCI Monograph 9. Bethesda, Md: National Cancer Institute, National Institutes of Health, Cancer Control and Population Sciences; 1998.
76. Henley SJ, Thun MJ, Chao A, et al. Association between exclusive pipe smoking and mortality from cancer and other diseases. J Natl Cancer Inst. 2004;96:853-861. (Pubitemid 38807606)
77. World Health Organization. TobReg-Advisory Note Waterpipe Tobacco Smoking: Health Effects, Research Needs and Recommended Actions by Regulators. Geneva: World Health Organization; 2005.
78. Quinn VP, Hollis JF, Smith KS, et al. Effectiveness of the 5-As tobacco cessation treatments in nine HMOs. J Gen Intern Med. 2009;24:149-154.
79. Hughes JR. Tobacco treatment specialists: a new profession. J Smoking Cessation. 2007;2(suppl):2-7.
80. Rubak S, Sandbaek A, Lauritzen T, et al. Motivational interviewing: a systematic review and meta-analysis. Br J Gen Pract. 2005;55:305-312. (Pubitemid 40520908)
81. Hurt RD, Dale LC, McClain FL, et al. A comprehensive model for the treatment of nicotine dependence in a medical setting. Med Clin North Am. 1992;76:495-514.
82. Zarling K, Burke M, Gaines K, et al. Registered nurse initiation of a tobacco intervention protocol: leading quality care. J Cardiovasc Nurs. 2008;23:443-448.
83. Hays JT, Wolter TD, Eberman KM, et al. Residential (inpatient) treatment compared with outpatient treatment for nicotine dependence. Mayo Clin Proc. 2001;76:124-133.
84. Croghan IT, Ebbert JO, Hurt RD, et al. Gender differences among smokers receiving interventions for tobacco dependence in a medical setting. Addict Behav. 2009;34:61-67.